J L Wallace

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow
    Camila L Santos
    Department of Physiology and Pharmacology, Federal University of Ceara, Rua Cel Nunes de Melo, 1127, CEP 60430 270, Fortaleza CE, Brazil
    Br J Pharmacol 146:481-6. 2005
  2. ncbi Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor
    John L Wallace
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada
    Br J Pharmacol 148:274-8. 2006
  3. ncbi Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?
    John L Wallace
    Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada
    Physiol Rev 88:1547-65. 2008
  4. ncbi A unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrient
    Mark J S Miller
    Center for Cardiovascular Sciences, Albany Medical College, Albany, New York, USA
    J Transl Med 6:3. 2008
  5. ncbi Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    J Pharmacol Exp Ther 309:626-33. 2004
  6. ncbi Potential cardioprotective actions of no-releasing aspirin
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
    Nat Rev Drug Discov 1:375-82. 2002
  7. ncbi COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation
    John L Wallace
    Inflammation Research Network, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    ScientificWorldJournal 6:577-88. 2006
  8. ncbi Selective cyclooxygenase-2 inhibitors: after the smoke has cleared
    J L Wallace
    Department of Pharmacology and Therapeutics, Calgary, Alberta, Canada
    Dig Liver Dis 34:89-94. 2002
  9. ncbi Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat
    John L Wallace
    Inflammation Research Network, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada
    Gastroenterology 132:261-71. 2007
  10. ncbi Building a better aspirin: gaseous solutions to a century-old problem
    J L Wallace
    Inflammation Research Network, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    Br J Pharmacol 152:421-8. 2007

Detail Information

Publications99

  1. ncbi Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow
    Camila L Santos
    Department of Physiology and Pharmacology, Federal University of Ceara, Rua Cel Nunes de Melo, 1127, CEP 60430 270, Fortaleza CE, Brazil
    Br J Pharmacol 146:481-6. 2005
    ..These results indicate that SILD, acting via NO-dependent mechanisms, prevents indomethacin-induced gastropathy, possibly through a reduction of leukocyte adhesion and maintenance of gastric blood flow...
  2. ncbi Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor
    John L Wallace
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada
    Br J Pharmacol 148:274-8. 2006
    ..However, as intact (rather than lysed) platelets were required for the accelerated healing, the presentation of VEGF by the platelet at the site of injury appears to be crucial for enhancement of the healing process...
  3. ncbi Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?
    John L Wallace
    Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada
    Physiol Rev 88:1547-65. 2008
    ....
  4. ncbi A unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrient
    Mark J S Miller
    Center for Cardiovascular Sciences, Albany Medical College, Albany, New York, USA
    J Transl Med 6:3. 2008
    ..We examined the therapeutic potential of a proprietary Croton palanostigma extract (Zangrado(R)) in the management of emesis and itch...
  5. ncbi Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    J Pharmacol Exp Ther 309:626-33. 2004
    ..NCX-2216 may represent an attractive alternative to conventional nonsteroidal anti-inflammatory drugs for long-term treatment of a variety of inflammatory disorders, especially those occurring in the central nervous system...
  6. ncbi Potential cardioprotective actions of no-releasing aspirin
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
    Nat Rev Drug Discov 1:375-82. 2002
    ..A modified version of aspirin that releases nitric oxide has been developed that seems to offer important advantages over its 103-year-old parent--namely, improved protection for the heart without the unwanted effects on the stomach...
  7. ncbi COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation
    John L Wallace
    Inflammation Research Network, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    ScientificWorldJournal 6:577-88. 2006
    ..In this review, the roles of COX-2 in mucosal defense and injury are discussed. Furthermore, contributions of COX-2-derived products to the long-term consequences of intestinal inflammation, including cancer, are reviewed...
  8. ncbi Selective cyclooxygenase-2 inhibitors: after the smoke has cleared
    J L Wallace
    Department of Pharmacology and Therapeutics, Calgary, Alberta, Canada
    Dig Liver Dis 34:89-94. 2002
    ....
  9. ncbi Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat
    John L Wallace
    Inflammation Research Network, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada
    Gastroenterology 132:261-71. 2007
    ..In this study, we evaluated the gastrointestinal safety and anti-inflammatory effects of a novel "HS-NSAID" (ATB-337) that consists of diclofenac linked to a hydrogen sulfide-releasing moiety...
  10. ncbi Building a better aspirin: gaseous solutions to a century-old problem
    J L Wallace
    Inflammation Research Network, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    Br J Pharmacol 152:421-8. 2007
    ....
  11. ncbi Selective cyclo-oxygenase-2 inhibitors: cardiovascular and gastrointestinal toxicity
    J L Wallace
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Alberta, Canada
    Dig Liver Dis 33:S21-8. 2001
    ....
  12. ncbi Hydrogen sulfide-releasing anti-inflammatory drugs
    John L Wallace
    Inflammation Research Network, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
    Trends Pharmacol Sci 28:501-5. 2007
    ..Such compounds have now been synthesized and shown to be markedly improved in many respects over the parent anti-inflammatory drugs...
  13. ncbi Prostaglandin biology in inflammatory bowel disease
    J L Wallace
    Mucosal Inflammation Research Group, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    Gastroenterol Clin North Am 30:971-80. 2001
    ..Such agents may permit clinicians to enhance mucosal repair selectively and to block selectively any contribution of prostaglandins to the pain associated with IBD...
  14. ncbi Commonality of defensive roles of COX-2 in the lung and gut
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Dr. NW, Calgary, Alberta, T2N 4N1 Canada
    Am J Pathol 168:1060-3. 2006
  15. ncbi The therapeutic potential of NO-NSAIDs
    John L Wallace
    f Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Fundam Clin Pharmacol 17:11-20. 2003
    ..Recent clinical trials of NO-NSAIDs have provided a 'proof of concept' that is completely consistent with pre-clinical characterization of these compounds...
  16. ncbi Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB
    John L Wallace
    Mucosal Inflammation Research Group, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, T2N 4N1, Canada
    J Pharmacol Exp Ther 310:1096-102. 2004
    ..These studies suggest that NCX-1024 may be an attractive alternative to conventional glucocorticoids, particularly for applications involving topical administration...
  17. ncbi Mucosal repair and COX-2 inhibition
    Rafael F Perini
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Curr Pharm Des 9:2207-11. 2003
    ..Given the importance of COX-2 in regulating ulcer healing, caution should be taken in the use of selective inhibitors of COX-2 by patients at risk of ulcer disease...
  18. ncbi Acetaminophen hepatotoxicity: NO to the rescue
    John L Wallace
    Department of Pharmacology and Therapeutics, Mucosal Inflammation Research Group, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    Br J Pharmacol 143:1-2. 2004
    ..There is also substantial evidence that a NO-releasing derivative of acetaminophen offers several advantages over acetaminophen itself, including enhanced analgesic potency and reduced liver toxicity...
  19. ncbi Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense
    John L Wallace
    Mucosal Inflammation Research Group, University of Calgary, Alberta T2N 4N1, Canada
    Br J Pharmacol 145:275-82. 2005
    ..COX-2 also contributes to long-term changes in GI function after bouts of inflammation...
  20. ncbi Nitric oxide as a regulator of inflammatory processes
    John L Wallace
    Mucosal Inflammation Research Group, Department of Pharmacology and Therapeutics, University of Calgary, Alberta T2N 4N1, Canada
    Mem Inst Oswaldo Cruz 100:5-9. 2005
    ..In recent years, NO-releasing drugs have been developed, usually as derivatives of other drugs, which exhibit very powerful anti-inflammatory effects...
  21. ncbi Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease
    J L Wallace
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Dig Liver Dis 35:S35-40. 2003
    ..Addition of a nitric oxide-releasing moiety to mesalamine significantly boosts its anti-inflammatory activity. NO-releasing mesalamine suppresses inflammatory cytokine production and reduces leukocyte infiltration...
  22. ncbi Lipoxins in gastric mucosal health and disease
    John L Wallace
    Mucosal Inflammation Research Group, Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alta, Canada T2N 4N1
    Prostaglandins Leukot Essent Fatty Acids 73:251-5. 2005
    ..These effects may be mediated via lipoxin-induced nitric oxide generation. Lipoxins activate a receptor that can also be activated by annexin-1, another substance involved in resolution of inflammation and gastroprotection...
  23. ncbi Recent advances in gastric ulcer therapeutics
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
    Curr Opin Pharmacol 5:573-7. 2005
    ..Recent studies support the notion that platelets make a major contribution to ulcer healing, and the release of several key growth factors from platelets appears to be regulated by proteinase-activated receptors...
  24. ncbi Inflammatory mediators in gastrointestinal defense and injury
    J L Wallace
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    Exp Biol Med (Maywood) 226:1003-15. 2001
    ..Many of these mediators are considered potential therapeutic targets for the treatment of ulcerative diseases of the digestive tract...
  25. ncbi Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats
    J L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 117:557-66. 1999
    ..We evaluated whether a similar derivatization of mesalamine (5-aminosalicylic acid) would improve its anti-inflammatory activity...
  26. ncbi Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity
    J L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Gastroenterology 115:101-9. 1998
    ..We investigated the relationship between suppression of inflammation by COX-2 inhibitors (NS-398, nimesulide, DuP697, and etodolac) and their effects on gastric prostaglandin synthesis...
  27. ncbi N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation
    J L Wallace
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Aliment Pharmacol Ther 13:1675-82. 1999
    ..In this study we investigated the ability of alendronate and pamidronate to directly damage the gastric epithelium and attempted to determine whether these drugs caused injury through gastric microcirculatory alterations...
  28. ncbi NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs
    John L Wallace
    University of Calgary, Department of Pharmacology and Therapeutics, Calgary, Alberta T2N 4N1, Canada
    Curr Opin Investig Drugs 9:1151-6. 2008
    ....
  29. ncbi Nitric oxide in mucosal defense: a little goes a long way
    J L Wallace
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 119:512-20. 2000
    ..We also review some of the main features of NO chemistry and the potential of NO as a target for new drugs to treat gastrointestinal disorders...
  30. ncbi NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2
    J L Wallace
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 119:706-14. 2000
    ..We tested this hypothesis in rats by using a selective COX-1 inhibitor (SC-560)...
  31. ncbi Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation
    John L Wallace
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    Am J Physiol Gastrointest Liver Physiol 286:G76-81. 2004
    ..These studies support the notion that NCX-4016 may be an attractive alternative to aspirin for indications such as cardioprotection, including in individuals also taking selective COX-2 inhibitors...
  32. ncbi Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release
    L Ma
    Mucosal Inflammation Research Group, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
    Proc Natl Acad Sci U S A 98:6470-5. 2001
    ..As shown with ticlopidine, drugs that influence gastric ulcer healing may do so in part through altering the ability of platelets to release growth factors...
  33. ncbi Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis
    Marcellus H L P Souza
    Dept. of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    Am J Physiol Gastrointest Liver Physiol 285:G54-61. 2003
    ..These results support the notion that aspirin-triggered lipoxin synthesis via COX-2 makes an important contribution to mucosal defense in both the normal and inflamed stomach...
  34. ncbi A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit
    J L Wallace
    Gastointestinal Research Group, University of Calgary, Alberta, Canada
    Gastroenterology 100:878-83. 1991
    ..Leukocytes might contribute to ulceration by occluding microvessels, thereby reducing mucosal blood flow, and by releasing various mediators, proteases, and free radicals that can produce tissue necrosis...
  35. ncbi Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation
    S Asfaha
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Am J Physiol Gastrointest Liver Physiol 281:G635-44. 2001
    ..Epithelial dysfunction of this type could underlie an increased propensity for further bouts of inflammation, a hallmark of diseases such as inflammatory bowel disease...
  36. ncbi Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(-) secretion in human intestinal epithelial cells
    M C Buresi
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    Am J Physiol Gastrointest Liver Physiol 281:G323-32. 2001
    ..This may be of clinical significance in inflammatory intestinal diseases with elevated thrombin levels...
  37. ncbi Protease-activated receptors in inflammation, neuronal signaling and pain
    N Vergnolle
    Mucosal Inflammation Research Group, Dept of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Alberta, T2N 4N1, Calgary, Canada
    Trends Pharmacol Sci 22:146-52. 2001
    ..Thus, the list of potential roles for PARs has lengthened considerably and their physiological course of action might be much broader than initially anticipated...
  38. ncbi Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction
    S R Zamuner
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    Gut 52:1714-20. 2003
    ..CONCLUSIONS: These studies demonstrate an important role for COX-2, possibly via generation of PGD2, in mediating the prolonged epithelial secretory and barrier dysfunction after a bout of colitis in the rat...
  39. ncbi Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist
    L Ma
    Mucosal Inflammation Research Group and Diabetes and Endocrine Research Group, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    Br J Pharmacol 134:701-4. 2001
    ..We conclude that thrombin-induced endostatin release from rat platelets is PAR4-mediated via an ADP-independent mechanism that can occur independently of platelet aggregation...
  40. ncbi Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors
    Rafael Perini
    Mucosal Inflammation Research Group, University of Calgary, Alberta
    Can J Gastroenterol 18:229-36. 2004
    ..Because of their safety profile, CINODs may be particularly useful for long term prevention applications, such as for colon cancer, cardiovascular disease and Alzheimer's disease...
  41. ncbi Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance
    Li Ma
    Mucosal Inflammation Research Group, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, AB, Canada T2N 4N1
    Proc Natl Acad Sci U S A 99:13243-7. 2002
    ..The absence of a delaying effect of HCT-1026 on ulcer healing may be related to the maintenance of a more favorable balance in serum levels of pro- and antiangiogenic growth factors...
  42. ncbi Intestinal platelet-activating factor synthesis during Nippostrongylus brasiliensis infection in the rat
    C M Hogaboam
    Gastrointestinal Sciences Research Group, Faculty of Medicine, University of Calgary, Alberta, Canada
    J Lipid Mediat 4:211-24. 1991
    ..Nevertheless, elevated PAF production is not simply a consequence of intestinal eosinophil and mast cell hyperplasia, as ileal PAF production did not significantly change despite hyperplasia of these cell types...
  43. ncbi Pathogenesis of NSAID-induced gastroduodenal mucosal injury
    J L Wallace
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Best Pract Res Clin Gastroenterol 15:691-703. 2001
    ..Through better understanding of the pathogenesis of ulcers induced by NSAIDs, some new approaches to the development of more effective and safer anti-inflammatory drugs have been taken in recent years...
  44. ncbi NSAID gastroenteropathy: past, present and future
    J L Wallace
    Intestinal Disease Research Unit, Faculty of Medicine, University of Calgary, Alberta
    Can J Gastroenterol 10:451-9. 1996
    ..Also reviewed are the strategies being employed to achieve this goal in the future...
  45. ncbi Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway
    N Vergnolle
    Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    Nat Med 7:821-6. 2001
    ..Here we identify a previously unrecognized nociceptive pathway with important therapeutic implications, and our results point to a direct role for proteinases and their receptors in pain transmission...
  46. ncbi Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury
    J L Wallace
    Gastrointestinal Research Group, University of Calgary, Alberta, Canada
    Am J Physiol 265:G993-8. 1993
    ....
  47. ncbi A magic bullet for mucosal protection...and aspirin is the trigger!
    John L Wallace
    Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    Trends Pharmacol Sci 24:323-6. 2003
  48. ncbi Gastrointestinal inflammation: a central component of mucosal defense and repair
    Gary R Martin
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Exp Biol Med (Maywood) 231:130-7. 2006
    ..Many of these endogenous factors, or the enzymes involved in their synthesis, are considered potential therapeutic targets for the treatment of diseases of the digestive tract that are characterized by inflammation and ulceration...
  49. ncbi Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats
    John L Wallace
    Inflammation Research Network, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 137:569-78, 578.e1. 2009
    ..The effects of H(2)S during the pathogenesis of colitis have not been established. We analyzed the contribution of H(2)S to inflammation and ulceration of the colon in a rat model of colitis...
  50. ncbi Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone
    Pierre-Yves von der Weid
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada
    Circulation 110:1320-5. 2004
    ..CONCLUSIONS: Aspirin-triggered lipoxin synthesis can modulate vascular tone, possibly contributing to changes in regional blood flow during inflammatory reactions, and to the modulation of systemic BP...
  51. ncbi Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation
    Renata C O Zanardo
    Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada
    FASEB J 20:2118-20. 2006
    ..These results suggest that endogenous H2S is an important mediator of acute inflammation, acting at the leukocyte-endothelium interface. These findings have important implications for anti-inflammatory drug development...
  52. ncbi Secretagogue-specific effects of interleukin-1 on gastric acid secretion
    J L Wallace
    Gastrointestinal Research Group, University of Calgary, Alberta, Canada
    Am J Physiol 261:G559-64. 1991
    ....
  53. ncbi Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2
    Stella R Zamuner
    Mucosal Inflammation Research Group, Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Dr. NW, Calgary, Alberta, T2N 4N1, and the Division of Gastroenterology, Kelowna General Hospital, British Columbia, Canada
    Am J Pathol 167:1293-300. 2005
    ..PGD2 may therefore represent a rational target for therapies directed at reducing the incidence of colitis-associated colorectal cancer...
  54. ncbi Citrobacter rodentium infection causes iNOS-independent intestinal epithelial dysfunction in mice
    Andrew C Skinn
    Mucosal Inflammation Research Group and Department of Physiology and Biophysics, University of Calgary, 3330 Hospital Dr NW, Calgary, AB T2N 4N1, Canada
    Can J Physiol Pharmacol 84:1301-12. 2006
    ..Citrobacter rodentium infection causes colonic inflammation, mucosal hyperplasia, and nitric-oxide-independent epithelial dysfunction in association with increased permeability to luminal bacteria...
  55. ncbi Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide
    J L Wallace
    Intestinal Disease Research Unit, University of Calgary, Alta
    Clin Invest Med 19:346-51. 1996
    ..g., mast cell reactivity) are reviewed, as is the evidence that these two groups of endogenous mediators cooperate in the modulation of mucosal defence...
  56. ncbi Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds
    C M Hogaboam
    Gastrointestinal and Immunological Sciences Research Group, University of Calgary, Alberta, Canada
    Br J Pharmacol 105:87-92. 1992
    ..This activity does not appear to be related to effects of these compounds on leukotriene synthesis or LTD4 receptors. The ability of these compounds to inhibit PAF synthesis may contribute to their anti-inflammatory properties...
  57. ncbi Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice
    D M McCafferty
    Immunology, Department of Physiology and Biophysics, University of Calgary, Alberta, Canada
    Am J Physiol Gastrointest Liver Physiol 279:G90-9. 2000
    ..These data suggest that iNOS does not impact on the development or severity of spontaneous chronic inflammation in IL-10-deficient mice...
  58. ncbi Annexin-1 modulates repair of gastric mucosal injury
    Gary R Martin
    Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada
    Am J Physiol Gastrointest Liver Physiol 294:G764-9. 2008
    ..These data support the hypothesis that annexin-1 contributes significantly to the process of healing of gastric mucosal damage...
  59. ncbi Acetic acid induced ulceration in rats is not affected by infection with Hymenolepis diminuta
    Derek M McKay
    Gastrointestinal Research Group, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada
    J Parasitol 95:481-2. 2009
    ..While the data do not dismiss the possibility that infection with other helminths could be anti-ulcerogenic, they illustrate that 'helminth therapy' for inflammatory disease is likely to be both disease- and helminth-specific...
  60. ncbi Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract
    Gary R Martin
    Inflammation Research Network, Department of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    Dig Liver Dis 42:103-9. 2010
    ..Little is known about H2S synthesis in the gastrointestinal tract. The aim of this study was to characterize H2S synthesis throughout the gastrointestinal tract...
  61. ncbi Hydrogen sulfide enhances ulcer healing in rats
    John L Wallace
    Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada
    FASEB J 21:4070-6. 2007
    ..The results further suggest that drugs releasing hydrogen sulfide could be employed to accelerate healing of gastric ulcers, and possibly of other wounds...
  62. ncbi Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection
    John L Wallace
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1, Canada
    Inflamm Allergy Drug Targets 5:133-7. 2006
    ..Lipoxins and nitric oxide are important mediators of mucosal defence in the stomach (and elsewhere in the gastrointestinal tract) and represent attractive therapeutic targets for reducing the incidence of gastric ulceration...
  63. ncbi Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis
    Eric Hyun
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Br J Pharmacol 143:618-25. 2004
    ....
  64. ncbi A role for proteinase-activated receptor-1 in inflammatory bowel diseases
    Nathalie Vergnolle
    Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
    J Clin Invest 114:1444-56. 2004
    ....
  65. ncbi A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner
    Genevieve K Dudar
    Inflammation Research Network, University of Calgary, Calgary, Alberta, Canada
    Am J Physiol Gastrointest Liver Physiol 295:G374-81. 2008
    ..The effects of the mimetic were independent of stimulatory effects on angiogenesis and COX-2 activity but were dependent on iNOS-derived NO production...
  66. ncbi Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis
    J L Wallace
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Alberta, Canada
    Regul Pept 73:95-101. 1998
    ....
  67. ncbi Characterization of leukotriene-induced contraction of the guinea-pig gallbladder in vitro
    S M Freedman
    Gastrointestinal Research Group, Faculty of Medicine, University of Calgary, Alta, Canada
    Can J Physiol Pharmacol 71:145-50. 1993
    ....
  68. ncbi Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets
    Li Ma
    Mucosal Inflammation Research Group and Diabetes-Endocrine Research Group, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    Proc Natl Acad Sci U S A 102:216-20. 2005
    ..These protease-activated receptors could therefore play a crucial role in regulating angiogenesis and in turn could regulate the processes of wound healing and tumor growth...
  69. ncbi Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage
    Renata C O Zanardo
    Mucosal Inflammation Research Group, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
    Am J Physiol Gastrointest Liver Physiol 288:G481-6. 2005
    ..We propose that in some circumstances, annexin-1 plays an important role as an endogenous mediator of mucosal defense...
  70. ncbi Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability
    Alex C Chin
    Department of Biological Sciences, University of Calgary, Calgary, AB, Canada T2N 1N4
    Proc Natl Acad Sci U S A 100:11104-9. 2003
    ..These results support a role for proteinases and PARs in intestinal disease and provide new directions for possible therapeutic applications of PAR1 antagonists...
  71. ncbi Roles of platelets and proteinase-activated receptors in gastric ulcer healing
    Rafael Perini
    Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    Dig Dis Sci 50:S12-5. 2005
    ..Taken together, our results suggest that PARs, including those expressed on platelets, are a rational therapeutic target for modulating healing processes and tumor growth...
  72. ncbi Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat
    Fusun Turesin
    Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Br J Pharmacol 139:966-72. 2003
    ..7. These results support the notion that delivery of NO to a site of inflammation can markedly enhance the anti-inflammatory activity of a glucocorticoid...
  73. ncbi Suppression of fever at near term is associated with reduced COX-2 protein expression in rat hypothalamus
    A Mouihate
    Neuroscience Research Group, Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Alberta, T2N 4N1 Canada
    Am J Physiol Regul Integr Comp Physiol 283:R800-5. 2002
    ..Altered expression of the EP3 receptor does not seem to be involved in this fever refractoriness at near term...
  74. ncbi Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells
    Mark Gilchrist
    Glaxo Heritage Asthma Research Laboratory, Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Leukoc Biol 71:618-24. 2002
    ..01), whereas unstimulated PMC released 2.1 +/- 0.3 microM/2 x 10(5) cells/48 h NO2-. These findings demonstrate that in vivo-derived PMC transcribe and translate mRNA for NOS and produce NO...
  75. ncbi Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis
    May M Chou
    Department of Biological Sciences, University of Calgary, 2500 University Drive, Calgary, Alberta, Canada, T2N 1N4
    Exp Biol Med (Maywood) 230:255-62. 2005
    ..The benefits of CS and GS in combination are more pronounced than those of CS alone. The reduction of arthritic disease by CS plus GS is associated with a reduction of IL-1beta and MMP-9 synthesis...
  76. ncbi Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism
    Cathy Nguyen
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    Can J Physiol Pharmacol 81:920-7. 2003
    ..These results implicate PAR2 as an important mediator of intestinal neurogenic inflammation...
  77. ncbi Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination
    Joseph M Antony
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Nat Neurosci 7:1088-95. 2004
    ..Thus, syncytin's proinflammatory properties in the nervous system demonstrate a novel role for an endogenous retrovirus protein, which may be a target for therapeutic intervention...
  78. ncbi A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis
    Kristina K Hansen
    Proteinases and Inflammation Network, Mucosal Inflammation Research Group, Department of Pharmacology, University of Calgary, Calgary, AB, Canada T2N 4N1
    Proc Natl Acad Sci U S A 102:8363-8. 2005
    ..rodentium-induced inflammation. These data point to an important role for both pathogen-induced host serine proteinases and PAR2 in the setting of infectious colitis...
  79. ncbi Resolution of inflammation: state of the art, definitions and terms
    Charles N Serhan
    Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Thorn 724, Boston, MA 02115, USA
    FASEB J 21:325-32. 2007
    ..Hence, resolution is an active rather than a passive process, as once believed, which now promises novel approaches for the treatment of inflammation-associated diseases based on endogenous agonists of resolution...
  80. ncbi A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway
    Stefano Fiorucci
    Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed Epatologia, Universita degli Studi di Perugia, Italy
    Br J Pharmacol 135:589-99. 2002
    ..Collectively, these observations suggest that APAP toxicity is Fas mediated and that NCX-701 spares the liver by acting at several checkpoints in the Fas pathway...
  81. ncbi Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction
    Anitaben Tailor
    Department of Molecular and Cellular Physiology, Health Sciences Center, Louisiana State University, 1501 Kings Highway, Shreveport, LA 71130 3932, USA
    Am J Physiol Heart Circ Physiol 293:H3636-42. 2007
    ..Platelet- and endothelial cell-associated COX-1 promote microvascular inflammation and thrombogenesis during hypercholesterolemia, yet nitric oxide-releasing aspirin directly inhibits platelets independent of COX-1...
  82. ncbi Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis
    Claudio Napoli
    Department of Medicine, Federico II University of Naples, 80131 Naples, Italy
    Proc Natl Acad Sci U S A 99:1689-94. 2002
    ..We suggest that an NCX-4016 derivative could be an effective drug in reducing restenosis, especially in the presence of aging and/or gastrointestinal damage...
  83. ncbi Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence
    Stefano Fiorucci
    Clinica di Gastroenterologia ed Endoscopia Digestiva, Policlinico Monteluce, 06100 Perugia, Italy
    J Pharmacol Exp Ther 309:1174-82. 2004
    ..In summary, our results support that ATL and NO are formed at the PMN/HUVEC interface after exposure to NCX-4016 and mediate the antiadhesive properties of this compound...
  84. ncbi Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice
    Paul T Jantzen
    Department of Pharmacology, Alzheimer s Research Laboratory, University of South Florida, Tampa, Florida 33612, USA
    J Neurosci 22:2246-54. 2002
    ..In conclusion, NCX-2216 is more efficacious than ibuprofen or celecoxib in clearing Abeta deposits from the brains of Tg mice, implying potential benefit in the treatment of Alzheimer's dementia...
  85. ncbi Role of cyclooxygenases in oedema-forming activity of bothropic venoms
    Renata do A Olivo
    Laboratory of Pharmacology, Butantan Institute, Avenida Vital Brazil 1500, 05503 900 Sao Paulo, SP, Brazil
    Toxicon 49:670-7. 2007
    ..In the case of BjV, COX-1-derived prostanoids also appear to contribute significantly to the inflammatory changes...
  86. ncbi Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit
    Giuseppe Rossoni
    Department of Pharmacological Sciences, University of Milan, Milan, Italy
    Br J Pharmacol 135:1540-6. 2002
    ..Cyclo-oxygenase-2 plays an important protective role in a setting of ischaemia-reperfusion of the heart...
  87. ncbi Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa
    Stefano Fiorucci
    Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e Sperimentale, Universita di Perugia, Italy
    Proc Natl Acad Sci U S A 100:10937-41. 2003
    ....
  88. ncbi Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin
    Stefano Fiorucci
    Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e Sperimentale, Universita degli Studi di Perugia, Perugia, Italy
    Br J Pharmacol 139:1351-9. 2003
    ....
  89. ncbi Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin
    Stefano Fiorucci
    Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e Sperimentale, Universita degli Studi di Perugia, Perugia, Italy
    FASEB J 17:1171-3. 2003
    ..These findings indicate that the balance between the production of LTB4 and ATL modulates PMN recruitment/function and gastric mucosal responses to aspirin...
  90. ncbi Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels
    Eleonora Distrutti
    University of Perugia, Clinica di Gastroenterologia, Policlinico Monteluce, Via Enrico Dal Pozzo, 06122 Perugia, Italy
    J Pharmacol Exp Ther 316:325-35. 2006
    ..This effect is mediated by K(ATP) channels and NO. H(2)S-releasing drugs might be beneficial in treating painful intestinal disorders...
  91. ncbi Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs
    Stefano Fiorucci
    Dipartimento di Medicina Clinica, Patologia, Clinica di Gastroenterologia ed Endoscopia Digestiva, University of Perugia, Italy
    Gastroenterology 129:1210-24. 2005
    ..Here, we have investigated the role of H(2)S in a rodent model of nonsteroidal anti-inflammatory drug (NSAID) gastropathy...
  92. ncbi Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2
    Nicolas Cenac
    Neuro Gastroenterology and Nutrition Unit, Institut National de la Recherche Agronomique, Toulouse, France
    Am J Pathol 161:1903-15. 2002
    ..Because trypsin and tryptase are found at high levels in the colon lumen of patients with Crohn's disease or ulcerative colitis, our data may bear directly on the pathophysiology of human inflammatory bowel diseases...
  93. ncbi Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage
    Stefano Fiorucci
    Clinica di Gastroenterologia ed Endoscopia Digestiva, Dipartimento di Medicina Clinica, Patologia e Farmacologia, , Perugia, Italy
    Gastroenterology 123:1598-606. 2002
    ..LXA4 exerts very potent protective actions on the gastric mucosa. Co-administration of aspirin and a selective COX-2 inhibitor results in substantially more severe gastric injury than is produced with either agent alone...
  94. ncbi Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo
    G Angus McQuibban
    Department of Biochemistry and Molecular Biology and the Biomedical Research Centre, University of British Columbia, Vancouver, Canada
    Blood 100:1160-7. 2002
    ..We propose that MMPs have an important role in modulating inflammatory and immune responses by processing chemokines in wound healing and in disease...
  95. ncbi COX-inhibiting nitric oxide donors (CINODs): potential benefits on cardiovascular and renal function
    Marcelo N Muscara
    Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av Prof Lineu Prestes 1524, Sao Paulo, 05508 900 SP, Brazil
    Cardiovasc Hematol Agents Med Chem 4:155-64. 2006
    ..The potential for CINODs to provide cardiorenal protection in humans is currently being investigated...
  96. ncbi Nitric oxide and inflammation
    Giuseppe Cirino
    Department of Experimental Pharmacology, Universita di Napoli Federico II, Napoli, Italy
    Inflamm Allergy Drug Targets 5:115-9. 2006
    ..At the present stage one of the most promising approach in the inflammation field is represented by a new class of NO-releasing compounds namely NO-NSAIDs that have recently enrolled in phase 2 clinical studies...
  97. ncbi The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver
    Stefano Fiorucci
    Dipartimenti di Medicina Clinica and Patologia, University of Perugia, Perugia, Italy
    Gastroenterology 131:259-71. 2006
    ..Inhibitors of hydrogen sulfide synthesis and drugs that can generate safe levels of hydrogen sulfide in vivo have been developed and are permitting interventional studies in experimental models and, in the near future, humans...
  98. ncbi 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity
    Eleonora Distrutti
    Clinica di Gastroenterologia, Policlinico Monteluce, University of Perugia, Via Enrico Dal Pozzo, 06122 Perugia, Italy
    J Pharmacol Exp Ther 319:447-58. 2006
    ..This study provides evidence that H(2)S-releasing drugs might have beneficial effects in the treatment of painful intestinal disorders...
  99. ncbi A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction
    Stefano Fiorucci
    Clinica di Gastroenterologia ed Endoscopia Digestiva, Dipartimento di Medicina Clinica e Patologia, Universita di Perugia, 06122 Perugia, Italy
    Proc Natl Acad Sci U S A 101:15736-41. 2004
    ..The combined antiinflammatory and immunomodulatory effects of ZK-192 in TNBS colitis suggest that ATL analogs may be an attractive oral treatment approach for inflammatory bowel diseases...